Article
Biochemistry & Molecular Biology
Chih-Wen Huang, Chen-Ta Yang, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang, Hsu-Heng Yen
Summary: This study compared the relapse rates of chronic hepatitis B patients after discontinuation of nucleos(t)ide analogues therapy with tenofovir alafenamide (TAF) and entecavir. The results showed that at 12 weeks after discontinuation, no patients in the entecavir group had relapsed, while three patients (7.9% cumulative rate) in the TAF group had relapsed. At 24 and 48 weeks, the cumulative rates of relapse in the entecavir and TAF groups were significantly different. Therefore, close monitoring of liver function and HBV DNA levels is necessary, especially within 24 weeks after discontinuation of TAF therapy.
Article
Gastroenterology & Hepatology
Chan-Young Jung, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
Summary: A study compared the risk of kidney function decline in treatment-naive chronic hepatitis B patients treated with ETV and TAF, finding that the risk was significantly higher in the ETV-treated group. Further prospective randomized studies are needed to confirm these findings.
LIVER INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Summary: The study found that CHB patients treated with ETV and TAF have similar risk of developing HCC, suggesting that further research with larger sample sizes and longer follow-up periods is needed for validation.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim
Summary: The study compared the effects of three antiviral agents on the risk of hepatocellular carcinoma and orthotopic liver transplantation or mortality in patients with chronic hepatitis B. It was found that the outcomes of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide were statistically similar in treatment-naive patients with CHB.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Microbiology
Wenting Peng, Huimin Gu, Da Cheng, Keyu Chen, Cichun Wu, Chuan Jiang, Jinqing Liu, Shifang Peng, Lei Fu
Summary: This study found that TAF is more effective than ETV in reducing viral load and improving survival rate in HBV-ACLF patients, and it also has a lower risk of renal function decline.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zhong-Bin Li, Le Li, Xiao-Xia Niu, Song-Hai Chen, Yi-Ming Fu, Chun-Yan Wang, Yan Liu, Qing Shao, Guofeng Chen, Dong Ji
Summary: The study aimed to evaluate the effectiveness and safety of switching from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in ETV-treated patients with low-level viraemia (LLV). Results showed that switching to TAF was safer and superior to continuing ETV in terms of virological and biochemical benefits. Both therapies were well tolerated and had satisfying renal safety.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Mindie H. Nguyen, Masanori Atsukawa, Toru Ishikawa, Satoshi Yasuda, Keisuke Yokohama, Huy N. Trinh, Taeang Arai, Shinya Fukunishi, Eiichi Ogawa, Yao-Chun Hsu, Mayumi Maeda, Hansen Dang, Cheng-Hao Tseng, Hirokazu Takahashi, Dae Won Jun, Tsunamasa Watanabe, Makoto Chuma, Akito Nozaki, Norifumi Kawada, Ramsey Cheung, Masaru Enomoto, Koichi Takaguchi, Hidenori Toyoda
Summary: The study showed that after an average of 6 years on ETV, patients who switched to TAF had an increased rate of complete viral suppression, and there were some changes in kidney function.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Jihye Lim, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Summary: Real-world data suggests that TAF and TDF have comparable efficacies in treating CHB, with similar virological responses and ALT normalization, and no higher risk of HCC.
LIVER INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Shao-Ming Chiu, Kuo-Chin Chang, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu, Chien-Hung Chen
Summary: This study compared the one-year retreatment efficacy and renal safety of entecavir, TDF, and TAF in patients with HBV relapse. The results showed no significant difference in virological response and ALT normalization among the three groups after 12 months of retreatment. Lower baseline levels of HBV DNA and HBsAg were independently associated with virological response at 12 months of retreatment. The TDF group had higher ALT levels at 12 months of retreatment, while the eGFR increased in the entecavir and TAF groups.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Lanqing Li, Jing Zhou, Yujing Li, Fada Wang, Dongmei Zhang, Menglan Wang, Yachao Tao, Enqiang Chen
Summary: This study compared the effectiveness and safety of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) in patients with chronic hepatitis B. The results showed that TMF had significant antiviral efficacy without adverse effects on renal function or blood lipids. Additionally, TMF was more efficient than TAF in inhibiting viral replication.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Takanori Ito, Junko Tanaka
Summary: The study found that hepatitis B patients experienced a faster reduction in HBsAg levels after switching from continuous entecavir therapy to a sequential therapy with entecavir and tenofovir alafenamide. Switching to tenofovir alafenamide may be an effective treatment option for reducing HBsAg levels.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Xuefeng Ma, Shousheng Liu, Mengke Wang, Yifen Wang, Shuixian Du, Yongning Xin, Shiying Xuan
Summary: The study found that the virological response in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) was significantly superior to those treated with entecavir (ETV), and the therapeutic effect of TDF+ETV was also better than TDF alone.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Yao-Chun Hsu, Dae Won Jun, Cheng-Yuan Peng, Ming-Lun Yeh, Huy Trinh, Grace Lai-Hung Wong, Sung Eun Kim, Chien-Hung Chen, Hyunwoo Oh, Chia-Hsin Lin, Lindsey Trinh, Vincent Wai-Sun Wong, Eilleen Yoon, Sang Bong Ahn, Daniel Huang, Yong Kyun Cho, Jae Yoon Jeong, Soung Won Jeong, Hyoung Su Kim, Qing Xie, Li Liu, Mar Riveiro-Barciela, Pei-Chien Tsai, Elena Vargas Accarino, Hidenori Toyoda, Masaru Enomoto, Carmen Preda, Sebastian Marciano, Joseph Hoang, Chung-Feng Huang, Ritsuzo Kozuka, Satoshi Yasuda, Doina Istratescu, Dong-Hyun Lee, Jia-Ying Su, Yen-Tsung Huang, Jee Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Man-Fung Yuen, Adrian Gadano, Ramsey Cheung, Seng Gee Lim, Maria Buti, Ming-Lung Yu, Mindie H. Nguyen
Summary: This study showed that there was no significant difference in the incidence of HBsAg seroclearance between ETV and TDF in patients with CHB, and this rarely occurred with either regimen.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Fa-Da Wang, Jing Zhou, Lan-Qing Li, Yu-Jing Li, Meng -Lan Wang, Ya-Chao Tao, Dong-Mei Zhang, Yong-Hong Wang, En-Qiang Chen
Summary: This study aimed to assess the incidence of renal and bone impairment in chronic hepatitis B (CHB) patients with long-term tenofovir disoproxil fumarate (TDF) therapy and to identify changes in bone mineral density (BMD) and renal function after switching to entecavir (ETV) or tenofovir alafenamide (TAF). The results showed that younger CHB patients on long-term TDF therapy are at a high risk for bone and renal impairment, which can be reduced when switched to ETV or TAF.
ANNALS OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Misako Tanaka, Takemi Akahane, Hideto Kawaratani, Nobuyuki Yorioka, Aritoshi Koizumi, Shohei Asada, Takuya Matsuda, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Koh Kitagawa, Kosuke Kaji, Tadashi Namisaki, Hitoshi Yoshiji
Summary: This study aims to investigate the long-term effects of entecavir and tenofovir alafenamide fumarate on renal function in elderly patients with chronic hepatitis B in Japan. The findings suggest that the change in estimated glomerular filtration rate after treatment is significantly greater in patients aged 65 years and older compared to those younger than 65 years.
HEPATOLOGY RESEARCH
(2023)